EGFR and colonic neoplasm: In conclusion, anti-EGFR monoclonal antibodies administered as a monotherapy have a substantial clinical effect in colon cancer, improving the survival of patients without K-RAS, N-RAS, or H-RAS mutations, commonly known as wild-type patients [64,65,66,67].